BR112022021204A2 - Polipeptídeos, proteínas heterodiméricas, ácido nucleico, células hospedeiras, método, composição farmacêutica e método de tratamento de uma espécie de animal de companhia, métodos para reduzir a atividade de sinalização de il13 e/ou il4 e para detectar il13 ou il4 em uma amostra - Google Patents

Polipeptídeos, proteínas heterodiméricas, ácido nucleico, células hospedeiras, método, composição farmacêutica e método de tratamento de uma espécie de animal de companhia, métodos para reduzir a atividade de sinalização de il13 e/ou il4 e para detectar il13 ou il4 em uma amostra

Info

Publication number
BR112022021204A2
BR112022021204A2 BR112022021204A BR112022021204A BR112022021204A2 BR 112022021204 A2 BR112022021204 A2 BR 112022021204A2 BR 112022021204 A BR112022021204 A BR 112022021204A BR 112022021204 A BR112022021204 A BR 112022021204A BR 112022021204 A2 BR112022021204 A2 BR 112022021204A2
Authority
BR
Brazil
Prior art keywords
polypeptides
heterodimeric proteins
methods
species
companion animal
Prior art date
Application number
BR112022021204A
Other languages
English (en)
Portuguese (pt)
Inventor
Jiann Li Shyr
Nguyen Lam
Chu Qingyi
Qian Fawn
Chin Richard
Zhan Hangjun
Original Assignee
Kindred Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kindred Biosciences Inc filed Critical Kindred Biosciences Inc
Publication of BR112022021204A2 publication Critical patent/BR112022021204A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5406—IL-4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/544—IL-14

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022021204A 2020-04-22 2021-04-22 Polipeptídeos, proteínas heterodiméricas, ácido nucleico, células hospedeiras, método, composição farmacêutica e método de tratamento de uma espécie de animal de companhia, métodos para reduzir a atividade de sinalização de il13 e/ou il4 e para detectar il13 ou il4 em uma amostra BR112022021204A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014090P 2020-04-22 2020-04-22
US202063014573P 2020-04-23 2020-04-23
PCT/US2021/028679 WO2021216899A1 (en) 2020-04-22 2021-04-22 Il4/il13 receptor molecules for veterinary use

Publications (1)

Publication Number Publication Date
BR112022021204A2 true BR112022021204A2 (pt) 2022-12-06

Family

ID=78270112

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021204A BR112022021204A2 (pt) 2020-04-22 2021-04-22 Polipeptídeos, proteínas heterodiméricas, ácido nucleico, células hospedeiras, método, composição farmacêutica e método de tratamento de uma espécie de animal de companhia, métodos para reduzir a atividade de sinalização de il13 e/ou il4 e para detectar il13 ou il4 em uma amostra

Country Status (10)

Country Link
US (1) US20240270819A1 (https=)
EP (1) EP4139344A4 (https=)
JP (1) JP7821741B2 (https=)
KR (1) KR20230005880A (https=)
CN (1) CN116034112A (https=)
AU (1) AU2021259785A1 (https=)
BR (1) BR112022021204A2 (https=)
CA (1) CA3173927A1 (https=)
MX (1) MX2022013149A (https=)
WO (1) WO2021216899A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102460040B1 (ko) 2016-04-27 2022-11-01 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
US11970526B2 (en) 2017-04-21 2024-04-30 Elanco Us Inc. IL4/IL13 receptor molecule for veterinary use
BR112020002871A2 (pt) 2017-08-15 2020-07-28 Kindred Biosciences, Inc. variantes fc de igg para uso veterinário
US12428466B2 (en) 2018-10-25 2025-09-30 Elanco Us Inc. IL4/IL13 receptor molecule for veterinary use
WO2025141037A1 (en) * 2023-12-28 2025-07-03 Elanco Animal Health Gmbh Il-4/il-13 and il-4/il-13/il-31 receptor trap constructs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023289A1 (en) * 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
SG10201404273QA (en) 2003-12-23 2014-10-30 Genentech Inc Novel anti-il 13 antibodies and uses thereof
AU2005219837A1 (en) 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. IL-4/IL-13 sepecific polypetides and therapeutic uses thereof
EP2596802A1 (en) * 2011-11-23 2013-05-29 PLS-Design GmbH Pharmaceutical composition for treatment of allergic reactions
US20170290889A1 (en) * 2016-04-11 2017-10-12 New York University Methods and compositions for treating dysbiosis and gastrointestinal and inflammatory disorders
CN110267674A (zh) * 2016-07-08 2019-09-20 奥美药业有限公司 包含瘦素的融合蛋白及其生产和使用方法
WO2018073185A1 (en) 2016-10-17 2018-04-26 Vetoquinol Sa Modified antibody constant region
US11970526B2 (en) * 2017-04-21 2024-04-30 Elanco Us Inc. IL4/IL13 receptor molecule for veterinary use
WO2024145280A2 (en) * 2022-12-27 2024-07-04 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
EP4642795A2 (en) * 2022-12-27 2025-11-05 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use

Also Published As

Publication number Publication date
EP4139344A4 (en) 2024-10-16
EP4139344A1 (en) 2023-03-01
US20240270819A1 (en) 2024-08-15
JP7821741B2 (ja) 2026-02-27
JP2023522676A (ja) 2023-05-31
AU2021259785A1 (en) 2022-11-17
CN116034112A (zh) 2023-04-28
KR20230005880A (ko) 2023-01-10
MX2022013149A (es) 2023-02-09
WO2021216899A1 (en) 2021-10-28
CA3173927A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
BR112022021204A2 (pt) Polipeptídeos, proteínas heterodiméricas, ácido nucleico, células hospedeiras, método, composição farmacêutica e método de tratamento de uma espécie de animal de companhia, métodos para reduzir a atividade de sinalização de il13 e/ou il4 e para detectar il13 ou il4 em uma amostra
BR112022021216A2 (pt) Anticorpos, ácido nucleico, célula hospedeira, composições farmacêuticas, métodos de produção de um anticorpo e de tratamento de uma espécie de animal de companhia e métodos para reduzir a função de sinalização de il31 em uma célula e para detectar il31 em uma amostra
Jex et al. The mitochondrial genomes of Ancylostoma caninum and Bunostomum phlebotomum–two hookworms of animal health and zoonotic importance
Arsenopoulos et al. Frequency of resistance to benzimidazoles of Haemonchus contortus helminths from dairy sheep, goats, cattle and buffaloes in Greece
Al Abri et al. Genome-wide scans reveal a quantitative trait locus for withers height in horses near the ANKRD1 gene
BRPI0606363A2 (pt) método para o isolamento e/ou a purificação de ácidos nucleicos ácido nucleico, e, método para a imobilização de ácidos nucleicos em uma matriz
RU2015111205A (ru) Генетические маркеры устойчивости к маститу
Nikmard et al. Calpastatin polymorphism in Afshari sheep and its possible correlation with growth and carcass traits
Mishra et al. Single nucleotide polymorphisms in 5’upstream region of bovine TLR4 gene affecting expression profile and transcription factor binding sites
Li et al. Molecular characterization of RIG-I, STAT-1 and IFN-beta in the horseshoe bat
Jabbar et al. The mitochondrial genome of Aelurostrongylus abstrusus—diagnostic, epidemiological and systematic implications
CN106086232B (zh) 一种用于鉴别羊口疮病毒和羊痘病毒的二重pcr检测引物、试剂盒和检测方法
CL2025001479A1 (es) Plantas y células vegetales modificadas
Wang et al. A novel 31bp deletion within the CDKL5 gene is significantly associated with growth traits in Dezhou donkey
Pal et al. Sequence characterization and polymorphism detection in bubaline CD14 gene
CA3101674A1 (en) In vitro method for monitoring the pathogen load in an animal population
Faggion et al. Genome-wide association study for weight loss at the end of dry-curing of hams produced from purebred heavy pigs
Pratiwi et al. Novel SNP of calpain-1 (CAPN1) gene and its association with carcass and meat characteristics traits in Bali cattle.
Rawat et al. Role of IL-6 and IL10 immune response genes against nematode Haemonchus contortus in ovis aries-a novel report
Safari et al. Identification of single nucleotide polymorphism in exon 3 of TLR4 gene and its association with somatic cell count in dairy cattle
Illig et al. TRPC4 ion channel protein is selectively expressed in a subpopulation of dopamine neurons in the ventral tegmental area
HINOJOSA et al. Exploring Host Defense in Xenopus laevis by Harvesting proteins and peptides from Frog Tissue Using Trizol Extraction and Analysis via Tandem Mass Spectrometry
Xu et al. Predictive Analysis of Susceptibility of Different Species to SARS-CoV-2 based on ACE2 Receptors
El-Mahdy Othman Mitochondrial DNA as a marker for genetic diversity and evolution
RU2011118970A (ru) Диагностический тест для выявления митохондриальной днк животных в кормах и мясных продуктах